Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Array BioPharma has reported that its monotherapy for first-line treatment of advanced melanoma has failed to meet the primary endpoint in a Phase II trial comparing the drug with temozolomide.
Subscribe to our email newsletter
There was no apparent difference in efficacy between AZD6244 and temozolomide for the primary endpoint, progression free survival. Although some anti-tumor activity was detected, AstraZeneca, which licensed AZD6244 from Array in 2003, said that it has no plans to progress the drug into Phase III trials.
AstraZeneca added that it is exploring other options to further develop this compound.